Literature DB >> 18991108

A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction.

Menggang Yu1, Seongho Kim, Zhiping Wang, Stephen Hall, Lang Li.   

Abstract

In drug-drug interaction (DDI) research, a two-drug interaction is usually predicted by individual drug pharmacokinetics (PK). Although subject-specific drug concentration data from clinical PK studies on inhibitor or inducer and substrate PK are not usually published, sample mean plasma drug concentrations and their standard deviations have been routinely reported. Hence there is a great need for meta-analysis and DDI prediction using such summarized PK data. In this study, an innovative DDI prediction method based on a three-level hierarchical Bayesian meta-analysis model is developed. The three levels model sample means and variances, between-study variances, and prior distributions. Through a ketoconazle-midazolam example and simulations, we demonstrate that our meta-analysis model can not only estimate PK parameters with small bias but also recover their between-study and between-subject variances well. More importantly, the posterior distributions of PK parameters and their variance components allow us to predict DDI at both population-average and study-specific levels. We are also able to predict the DDI between-subject/study variance. These statistical predictions have never been investigated in DDI research. Our simulation studies show that our meta-analysis approach has small bias in PK parameter estimates and DDI predictions. Sensitivity analysis was conducted to investigate the influences of interaction PK parameters, such as the inhibition constant Ki, on the DDI prediction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991108      PMCID: PMC2737821          DOI: 10.1080/10543400802369004

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  29 in total

Review 1.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

Authors:  K Ito; T Iwatsubo; S Kanamitsu; K Ueda; H Suzuki; Y Sugiyama
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

2.  Strategic proposals for predicting drug-drug interactions during new drug development: based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5-fluorouracil prodrugs.

Authors:  T Watabe
Journal:  J Toxicol Sci       Date:  1996-12       Impact factor: 2.196

3.  Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.

Authors:  L L von Moltke; D J Greenblatt; J Schmider; S X Duan; C E Wright; J S Harmatz; R I Shader
Journal:  J Clin Pharmacol       Date:  1996-09       Impact factor: 3.126

4.  Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.

Authors:  M Bourrié; V Meunier; Y Berger; G Fabre
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030

5.  Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.

Authors:  S A Wrighton; B J Ring
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

6.  Pharmacokinetics of ketoconazole in normal subjects.

Authors:  T K Daneshmend; D W Warnock; A Turner; C J Roberts
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

7.  Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.

Authors:  H Okuda; T Nishiyama; K Ogura; S Nagayama; K Ikeda; S Yamaguchi; Y Nakamura; K Kawaguchi; T Watabe; Y Ogura
Journal:  Drug Metab Dispos       Date:  1997-02       Impact factor: 3.922

8.  Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.

Authors:  Jenny Y Chien; Aroonrut Lucksiri; Charles S Ernest; J Christopher Gorski; Steven A Wrighton; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2006-04-12       Impact factor: 3.922

9.  Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.

Authors:  M A Gibbs; K E Thummel; D D Shen; K L Kunze
Journal:  Drug Metab Dispos       Date:  1999-02       Impact factor: 3.922

10.  In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.

Authors:  L L von Moltke; D J Greenblatt; S X Duan; J S Harmatz; R I Shader
Journal:  J Clin Pharmacol       Date:  1994-12       Impact factor: 3.126

View more
  5 in total

1.  Literature mining on pharmacokinetics numerical data: a feasibility study.

Authors:  Zhiping Wang; Seongho Kim; Sara K Quinney; Yingying Guo; Stephen D Hall; Luis M Rocha; Lang Li
Journal:  J Biomed Inform       Date:  2009-04-02       Impact factor: 6.317

Review 2.  Text mining for drug-drug interaction.

Authors:  Heng-Yi Wu; Chien-Wei Chiang; Lang Li
Journal:  Methods Mol Biol       Date:  2014

3.  Non-compartment model to compartment model pharmacokinetics transformation meta-analysis--a multivariate nonlinear mixed model.

Authors:  Zhiping Wang; Seongho Kim; Sara K Quinney; Jihao Zhou; Lang Li
Journal:  BMC Syst Biol       Date:  2010-05-28

4.  A new probabilistic rule for drug-dug interaction prediction.

Authors:  Jihao Zhou; Zhaohui Qin; Sara K Quinney; Seongho Kim; Zhiping Wang; Menggang Yu; Jenny Y Chien; Aroonrut Lucksiri; Stephen D Hall; Lang Li
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-01-21       Impact factor: 2.745

5.  Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model.

Authors:  T A Leil; S Kasichayanula; D W Boulton; F LaCreta
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-06-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.